Ranvir's Portfolio

Bank of Maharashtra -

Q4 and FY 26 results and concall highlights -

FY 26 outcomes -

Deposits @ 3.5 lakh cr, up 14 pc

Advances @ 2.91 lakh cr, up 21 pc

C/D ratio @ 83 pc

Gross NPAs @ 1.45 vs 1.74 pc

Net NPAs @ 0.13 vs 0.18 pc

PCR @ 98.6 vs 98.3 pc !!!

CASA ratio @ 52.51 pc !!! ( CASA deposits grew by 12 pc on a YoY basis )

NII @ 13664 cr, up 17 pc

Operating profits @ 10826 cr, up 16 pc

Provisions @ 3807 cr, flat YoY

PAT @ 7019 cr, up 27 pc

Cost/Income @ 37.1 pc - very healthy levels

NIMs @ 3.91 pc

RoA @ 1.86 pc

RoE @ 23.19 pc

Cost of deposits @ 4.52 vs 4.66 pc

Cost of funds @ 4.15 vs 4.22 pc

Yield on advances @ 9.03 vs 9.21 pc

Yield on funds @ 7.78 vs 7.72 pc

Breakup of loan book -

Retail loans @ 85.8 vs 64.8 k cr, up 32 pc

Agri loans @ 40.2 vs 35.5 k cr, up 13 pc

MSME loans @ 53.54 vs 48.36 k cr, up 10 pc

Total RAM loans @ 63 pc of bank’s loan book

Corporate loans @ 1.06 vs 0.91 lakh cr, up 16 pc ( @ 36 pc of bank’s loan book )

Overseas loans @ 6.1 k cr - new vertical

Q4 FY 26 outcomes -

NII @ 3702 cr, up 18 pc

Operating profit @ 2946 cr, up 17 pc

Provisions @ 932 cr, down 9 pc

PAT @ 2014 cr, up 35 pc

NIMs @ 3.91 pc

RoA @ 1.97 pc

Cost / Income @ 36.51 pc

Notes from Q4 concall -

Retail growth in FY 26 was led by -

Housing loans - up 29 pc

Vehicle + Gold loans - up 53 pc

Corporate loan growth was also strong mainly led by sectors like - Infra, Green Energy, Data Centers

Recoveries in last 2 FYs has been @ 1300 cr and 1400 cr respectively

Q1, Q2, Q3 and Q4 NIMs stood @ 3.95, 3.85, 3.91 and 3.95 respectively - despite a rate cut cycle that played out during the FY

Guiding for RoA @ 1.8 pc for FY 27

Capital adequacy stands @ 18.36 pc

Bank’s shareholding - GoI holding @ 73 pc, FII holdings @ 5.8 pc, DII holdings @ 6.8 pc. FII and DII holdings have improved sharply in last 3-4 yrs

Till now - have not seen any meaningful impact on asset quality from the Iran war. Expecting some stress to flow through wef Q2

Have provisioned an additional 200 cr - due breakout of Iran war. It’s a voluntary step - not mandated by the RBI. May do the same in Q2, Q3 as well

Overseas book should cross 9k cr in FY 27. Have already achieved break even wrt their overseas business ( being operated from Gift city )

Wef FY 27, company would be paying 18 pc corporate tax rate. Previous tax benefits now stand exhausted. This should cap the bank’s PAT growth for FY 27 ( as ETR for FY 26 was only @ 11 pc vs 18 pc expected for FY 27 )

Total branches as on 31 Mar 26 @ 2871. Aim to open 1000 new branches over next 5 yrs

State wise distribution of bank’s branches ( top 5 states ) -

Maharashtra - 1229

MP -165

UP - 115

Gujarat - 85

Karnataka - 70

Guidance for next FY -

Advances growth - 18 pc

Deposits growth - 15 pc

RAM book growth @ 18 pc

NII @ 15 pc

NIM @ 3.75 pc

Cost / Income @ < 40 pc

RoA @ 1.8 pc

RoE > 20 pc

Slippages below 1 pc

NNPAs below 0.25 pc

Company’s non interest income has grown by a paltry 3 pc vs a guidance of 10 pc growth due to some exceptional circumstances in FY 26. This growth should bounce back in FY 27

Maharashtra Govt has announced a one time farm loan waiver for loans upto 2 lakh / farmer. Since the bank had outstanding farm loans that had slipped into NPAs, they may now receive payments from the state Govt to the tune of aprox 2000 cr - over next 1-2 yrs. farmers who have paid in time, will get a one time credit of Rs 50k into their savings bank account

Gold loan book now @ 24k cr. Have signed up with 9 top NBFCs for Gold loan Co Lending arrangements

Segment wise slippages ( aprox ) in Q4 -

Retail - 100 cr

Agri - 300 cr

MSME - 400 cr

Corporate - NIL

Bank doesn’t lend to retail customers with credit score below 680. Similarly, have tightened their lending norms for MSME players

Disc: not holding, not SEBI registered, posted only for educational purposes

1 Like

Fed Bank Fin Services -

Q4 FY 26 results and Concall highlights -

Q4 outcomes -

NII - 348 vs 283 cr

Other income - 29 vs 38 cr

Total income - 378 vs 321 cr, up 17 pc

Operating expenses - 215 vs 190 cr, up 13 pc

Operating profits - 162 vs 131 cr, up 24 pc

Credit costs - 28 vs 32 cr - sharp improvement

PAT - 100 vs 71 cr, up 40 pc

No of branches - 757 vs 694 - opened 63 new branches in FY 26

Employee count @ 5303 vs 4568

AUM @ 20153 vs 15812 cr, up 27 pc

Gold loans @ 10352 ( avg ticket size @ 2.7 lakh )

Medium Ticket LAPs @ 5570 cr ( avg ticket size @ 72 lakh )

Small Ticket LAPs @ 3782 cr ( avg ticket size @ 16 lakh )

Statewide breakup of branches -

TN - 90

Karnataka - 95

Maharashtra - 141

Gujarat - 136

AP - 57

Telangana - 42

Rajasthan - 34

MP - 20

UP - 22

Delhi - 46

Haryana - 32

Punjab - 14

Uttarakhand - 8

Spreads, Yields, COFs for FY 26 -

Avg yeilds @ 16.7 pc

COFs @ 8.6 pc

Spreads @ 8.1 pc

Percentage of off book assets in the Gold loan portfolio @ 23 pc

Percentage of off book assets in LAP portfolio @ 33 pc

Asset Quality trends -

GNPAs @ 1.9 vs 2 pc YoY

NNPAs @ 1.3 vs 1.2 pc YoY

PCR @ 32 vs 40 pc YoY

1 DPD + @ 6 vs 7.3 pc of AUM - substantial improvement

30 DPD + @ 3.7 vs 4.7 pc of AUM - substantial improvement

60 DPD + @ 2.3 vs 2.6 pc of AUM - substantial improvement

Notes from Q4 concall -

Within LAP, company intends to keep focusing on high risk ST LAP and low risk MT LAP and shall strive to strike a balance between the two to manage overall risk at company level

Cost / Income in FY 27 shall start to improve meaningfully vs FY 26 as the operating leverage keeps kicks in

Previously, the company had not invested adequately in their collection teams. ST LAP is a collections heavy business. Company has corrected this over last 12 months by rapidly expanding their internal collections team. Should see much better collections and asset quality going forward in their LAP vertical

Disbursements in Q4 -

MT LAP disbursals in Q4 @ 632 cr

ST LAP disbursals in Q4 @ 289 cr

Gold loan disbursals in Q4 @ 10,744 cr - since they r short tenured loans

Segment wise yeilds -

Gold loans - 17.7 pc, Avg LTV @ 70 pc

MT LAP - 12 pc, Avg LTV @ 53 pc

LT LAP - 15.1 pc Avg LTV @ 54 pc

FY 26 vs FY 25 credit costs @ 0.8 pc vs 1.5 pc - substantial improvement

Opex to AUM @ 5.5 vs 5.9 pc YoY - operating leverage playing out slowly but surely

Annual RoA @ 2.6 vs 2.2 pc

Annual RoE @ 14 pc vs 9 pc

Small ticket LAP should turn around wef next FY. Company is far more confident vs LY. Their expanded recovery teams are now in place and are relatively experienced by now. Growth should now come back in this segment

Fee income in FY 26 was relatively tepid as the disbursals on LAP segments were on the slower side. This should also reverse going forward - as the management now intends to grow both their ST and MT LAP businesses at accelerated pace

Aim to keep growing their AUM @ 20-25 pc over medium term

Company’s gold tonnage is up 12 pc YoY ( vs 75 pc AUM growth in gold loans )

Company’s avg gold loan / branch is @ 16 cr. Most of these branches have a peak gold loan disbursement capacity of 50-60 cr - depending on the no of lockers and their sizes that are available

FY 26 was a re-build year for the company. In FY 27, RoAs and RoEs should be better as operating leverage kicks in and credit costs remain under control

Disc: holding, biased, investment position, not SEBI registered, posted only for educational purposes

1 Like

RPG Lifesciences -

Q4 and FY 26 Concall highlights -

Q4 outcomes -

Revenues - 177 vs 143 cr, up 23 pc

EBITDA - 45 vs 30 cr, up 48 pc ( margins @ 25.6 vs 21.4 pc - massive margins expansion )

PAT - 29 vs 19 cr, up 56 pc

Domestic formulations grew @ 18 pc in Q4 vs an IPM growth of 10 pc - massive outperformance reported by the company

FY 26 outcomes -

Revenues - 707 vs 653 cr, up 8 pc ( company lost API sales in FY 26 due to a fire incident @ one of their manufacturing blocks )

EBITDA - 172 vs 172 cr, flat ( margins @ 24.4 vs 26.4 pc )

PAT - 111 vs 111 cr, flat

Segmental sales in FY 26 -

Domestic formulations - 483 vs 425 cr, up 14 pc ( 69 pc of company revenues )

International formulations - 123 vs 132 cr, down 7 pc

APIs - 95 vs 90 cr, up 6 pc

Domestic MR productivity @ above 6.5 lakh

Notes from previous Concalls -

Actively looking at inorganic opportunities ( both brands and small companies ) to accelerate growth in the domestic business

Looking to enter nice molecules / combinations that are currently not avlb in the country + difficult to make molecules

Company is working hard at mainstreaming Naproxen by educating doctors on benefits of Naproxen vs Ibuprofen / Diclofenac in the NSAID space

Norpace is another brand ( used to treat irregular heart beat ) where the company is literally the only big player in the mkt. However, the awareness about this particular disease is low and its company’s responsibility to grow this category by spreading awareness and educating doctors / patients

Have got an approval in Canada to move Naprosyn ( Naproxen ) from a prescription to OTC category. Company intends to do the same in India as well ( over medium term )

Notes form Q4 Concall -

Naprosyn grew 15 pc in FY 26 and 24 pc in Q4

Immunosupressants portfolio ( anchored by large brands like Azoran and Mofetyl ) continued to show steady traction

Biologics portfolio ( have launched Bevacizumab, Adalimubab, Rituximab, Trastuzumab in IPM ) grew at 12 pc for FY 26. Its a high growth, margin accretive business for the company

Norpace grew 50 pc in FY 26

Serenace ( Haloperidol ) is another promising brand - now picking up pace

International Formulation sales were adversely affected by inventory rationalisation by some of their customers. Canada, SE Asia and Africa remain their key focus geographies

Cash on books @ 275 cr despite spending aprox 140 cr over last three years towards their plant modernisation efforts

Q4 volume growth was @ 9 pc. New product introductions contributed to 5 pc growth

FY 26 volume growth stood @ 7 pc, New product introductions contributed to 4 pc growth

Have a good pipeline of new product launches lined up in Cardiology, Urology segments + newer variants of Naprosyn - in domestic mkts

Have tied up with WalMart for OTC sales of Naprosyn. Should be able to launch by Sep 26 - after meeting all regulatory compliances

Going forward - API business should also become a major growth driver for the company. Have 13 products under development

New product launches in IPM should have higher GMs vs company’s current GMs

Disc: holding, investment position, biased, not a buy/sell recommendation, not SEBI registered, posted only for educational purposes

2 Likes

IIFL Finance -

Q4 and FY 26 results and concall highlights -

Q4 outcomes -

NII - 1163 cr, up 13 pc

Income from off book assets - 773 cr, up 189 pc

Other income - 153 cr, up 73 pc

Total Income - 2090 cr, up 51 pc

Operating expenses - 917 cr, up 25 pc

Pre Prov Operating profit - 1172 cr, up 80 pc

Loan losses + Provisions - 325 cr, down 7 pc

PAT - 586 vs 207 cr, up 183 pc

Consol AUM as on 31 Mar @ 1.08 lakh cr

Breakup of AUM -

Gold loans - 57.6 k cr ( out of which, off book assets @ 20.4 k cr - comprising of 36 pc of total loan book ) - grew 150 pc YoY

Home finance + LAP - 40.07 k cr ( out of which, off book assets @ 14.5 k cr - comprising of 36 pc of total loan book ) - grew 2 pc YoY

Micro Finance - 10.5 k cr ( out of which, off book assets @ 3.03 k cr, comprising of 29 pc of total loan book ) - degrew by 7 pc YoY

Off book assets include both - Co Lending and Assigned loans

Discontinued business - 2.6 k cr - down 48 pc YoY

Company has CoLending arrangements with PNB, BoB, UCO, IDBI, South Indian Bank, DCB, RBL. New banks onboarded in Q4 include - JK Bank, Central bank of India, BoM

Segmental Yields -

Home loans - 10.55 pc

Gold loans - 18.12 pc

MSME secured loans - 15.61 pc ( in most cases, residential / commercial property is the collateral )

MSME unsecured - 17.72 pc - company intends to go slow here

Microfinance - 24.5 pc

On a consolidated basis -

Avg yeilds @ 16.3 pc

Avg cost of borrowing @ 8.97 pc

Avg spreads @ 7.32 pc

Segmental GNPAs for Q4 -

Home loans - 0.81 vs 1.41 pc

Gold loans - 0.35 vs 0.54 pc

MSME secured - 2.65 vs 1.77 pc

MSME unsecured - 3.36 vs 1.75 pc

MicroFinance - 3.87 vs 4.81 pc

Consol GNPA @ 1.46 vs 2.23 pc - signifiant improvement

Consol NNPA @ 0.73 vs 1.05 pc - signifiant improvement

Notes from Q4 concall -

Since company’s lines of business are diversified across different lending spaces, company isn’t facing borrowing challenges wrt their MFI business. Some Standalone MFI organisations are facing these challenges - as Banks are cautious that they may not be able to survive the LY’s turmoil in the micro finance space

Q4 annualised RoE, RoA stood @ 18 pc, 2.79 pc - showing a sharp turnaround

IT assessment order is expected in a few days. We ll know of IT dept’s demands once the assessment order is out. Company believes, they need not pay anything extra. However, if the order is contradictory - they ll appeal against it

Expect to grow their Consol loans AUM by 20-25 pc for FY 27 - even if the gold prices don’t rise from hereon

In medium term, company intends to de-merge into 3 entities - IIFL Gold and MSME loans, IIFL home finance, IIFL Samasta Finance ( Microfin arm )

Credit cost, RoA expectation for FY 27 is around 1.7 pc, 3.25 pc

Company intends to ramp up its Off book AUM ( CL + DA ) to 40-42 pc vs 35 pc at present. Presently Co Lending book is @ 13 pc and DA book is @ 23 pc of AUM

Expecting Gold loans AUM grow @ 20-25 pc, Housing loans AUM to grow @ 18-20 pc for next FY

Another advantage of growing off book assets is that they won’t need to raise capital in near future

RoE and RoA in home loans and micro finance continue to remain subdued ( single digit RoEs ). As the growth picks up in these 2 segments, the return ratios should start to see meaningful improvement wef FY 27. Currently offer affordable segment HLs from 221 branches and emerging HLs from 94 branches. Aim to ramp up to > 300 branches for affordable loans in next FY. Affordable loans are loans below 25 lakh. Emerging HLs are loans between 25-50 lakh ticket size

Affordable loans are also eligible for PMAY 2.0 subsidies. Its a natural tailwind for this segment

LAP constitutes 18 pc of company’s total housing loans book. Here the yeilds are higher. Intend to grow aggressively in this segment as well

Aim to move RoE of Housing loans business into double digits in FY 27

IIFL Samasta - intend to aggressively grow micro LAPs wef next FY. Avg ticket size for the company in this segment is around 4.8 lakh. For micro finance loans, their avg ticket size is around 70k

Intend to ramp up IIFL Samata’s loan book AUM to 14k cr ( closing levels in FY 24 ) from 10.5k cr ( closing levels in FY 26 ). Samasta reported a PAT of 503 cr in FY 24 vs 20 cr and 21 cr in FY 25 and FY 26

Company’s credit rating is AA ( two notches - AA+ and AAA below the best ). Once they achieve AAA rating, their CoF are expected to fall by aprox 100 bps

Disc: holding, investment position, biased, not SEBI registered, not a buy/sell recommendation, posted only for educational purposes

2 Likes

Evereday Industries -

Q4 and FY 26 results and concall highlights -

Q4 outcomes -

Revenues - 327 vs 299 cr, up 9.4 pc

EBITDA - 29 vs 26 cr, up 10 pc ( margins @ 8.8 vs 8.7 pc )

PBT - 16 vs 12 cr, up 33 pc

Exceptional item - 118 cr ( divestment of surplus land in Noida )

PAT - 141 vs 10 cr

Segmental sales for Q4 -

Batteries - 224 cr, up 9 pc

Flashlights - 29 cr, up 3 pc

Lighting - 80 cr, up 17 pc

FY 26 outcomes -

Revenues - 1455 vs 1344 cr, up 8 pc

EBITDA - 167 vs 153 cr, up 9 pc ( margins @ 11.5 vs 11.3 pc )

PBT - 118 vs 98 cr, up 20 pc

Exceptional items - 48 cr ( land sale, arbitration settlement, implementation of new labour codes, payment of one time Ex-Gratia against compulsory retirement of workmen )

PAT - 171 vs 82 cr

Segmental sales for FY 26 -

Batteries - 971 cr, up 9 pc

Flashlights - 179 cr, up 3 pc

Lighting - 341 cr, up 8 pc

Closing Net Debt @ 178 cr vs 282 cr on 31 Mar 25 - substantial debt reduction primarily on account of sale of surplus land parcel

Notes from previous concalls -

New products launched in last 12 months include - Irons, room heaters, immersion rods, mosquito racquets, charging devices, extension boards, bells, multi plugs, power banks

Their Mkt share in Alkaline battery segment at the end of FY 23 and FY 24 was 4 pc and 9 pc respectively vs 19 percent at the end of Q3 FY 26

Mandatory BIS certification should make it difficult for unorganised players to compete in the flashlights segment - which should help the company

Jammu plant will have capacities so that the company can supply Alkaline batteries to other branded players in India + for exports to ME, African, other Asian mkts

Jammu plant has the capacity to make 35 cr batteries / yr at peak capacity utilisation. Should be able to produce and sell 10 cr batteries from this plant in FY 27 ( assuming 30-40 pc growth in alkaline batteries in next FY )

Jammu plant should be eligible for GST refund incentives ( yet to achieve their registration certificate )

Notes from Q4 concall -

Higher Zinc prices are a constant source of RM inflation

Alkaline batteries now account for 10 pc of company’s battery business

Have taken price hikes in Q3 and Q4 in C-Zn battery segment - to offset higher Zinc prices

Rapidly gaining mkt share in electric Mosquito racket segment

Rechargeable flashlights continue to grow well. Battery operated flashlights is already a mature segment

Commissioned Alkaline Battery manufacturing facility @ Jammu on 22 Apr 26. Have spent a total of 200 cr towards this facility. It’s the only Alkaline manufacturing facility in India. Commercial production should start in early May 26

Assuming an avg selling price of Rs 20 / alkaline battery ( also assuming lower selling price wrt contract manufacturing sales ), if the company is able to sell an additional 10 cr batteries ( as guided ) - they should be able to clock 200 cr in additional sales

Alkaline battery segment is growing @ 20 pc CAGR in volume terms. Should capture > 30 pc mkt share in India over next 5-6 yrs from 15 pc kind of mkt share today

Initially, margins from Jammu plant’s output should be below company level margins. They would improve only when the capacity ramps up further in next 2 yrs or so

Company’s current mkt share in Alkaline batteries is 16 pc. Should exit FY 27 with > 20 pc mkt share

The new Jammu facility also has the capacity to make C-Zn batteries, lighting and flashlights

Awaiting for Govt clarity on GST benefits wrt production out of Jammu facility

Have also launched LiIon AA and AAA batteries ( last yr ). These batteries last far longer than even the premium Alkaline batteries. Aprox cost of these batteries is around 250 / battery

Expecting to grow Alkaline battery volumes in an aggressive fashion in next 2-3 yrs

Given the current inflationary scenario, can expect another round of price hikes in both C-Zn and Alkaline segments

Last reported segmental EBITDA margins ( as reported in Q1 FY 26 ) stood @ -

Batteries - 19 pc

Flashlights - 13 pc

Lighting - breakeven

Jammu plant should help company expand GMs of Alkaline segment by 10 pc

Current EBITDA margins of value alkaline ( Ultima ) are similar to Caron Zinc batteries. Premium alkaline ( Ultima Pro ) batteries have higher margins. Anyways - as Jammu plant ramps up, margins of both types of Alkaline batteries should inch higher

Have another Plot in Noida - to be sold. Should fetch another 130 cr or so for the company. Have already recieved aprox 45 cr against the sale of the same. Should receive the remaining amount in FY 27

Disc: holding, biased, not SEBI registered, may add more, posted only for educational purposes

1 Like

Five Star Business finance -

Q4 and FY 26 results and concall highlights -

AUM @ 13.24 vs 11.87 k cr, up 11 pc ( managed to grow their AUM despite one of the toughest years in recent times )

NII @ 644 vs 584 cr, up 10 pc

Operating expenses @ 227 vs 187 cr, up 21 pc

Credit costs @ 60 vs 25 cr, up 138 pc

PAT - 269 vs 279 cr, down 3 pc

Cost / Income @ 41.82 vs 35.05 pc - due increased provisioning + expanded branches and employee base

RoE @ 16.06 vs 18.68 pc

Q4 disbursements @ 1213 vs 973 cr in Q3

Portfolio yeild @ 22.58 vs 23.7 pc - YoY

Cost of borrowing @ 8.95 vs 9.63 pc - YoY

Spreads @ 13.63 vs 14.07 pc - YoY

Asset quality trends -

1 DPD + @ 17.31 pc vs 18.23 and 18.33 pc in Q3 and Q2

30 DPD + @ 12.69 pc and 12.81 and 12.17 pc in Q3 and Q2

GNPAs @ 3.37 pc vs 3.18 and 2.64 pc in Q3 and Q2

NNPAs @ 2 pc vs 1.94 and 1.45 pc in Q3 and Q2

PCR on GNPAs @ 41.4 pc

PCR on AUM @ 1.84 pc

X Bucket collection efficiency @ 99.3 pc vs 99 pc in Q3 ( ie collections percentage from standard customers ) - an indicator of forward flow of slippages

Unique Customer collection efficiency @ 98.1 pc vs 97.26 in Q3 - on of the best in company’s history ( ie collection percentage form Standard + 1DPD+ customers - GNPA customers )

Slippage ratio @ 0.70 pc vs 1.09 and 0.69 pc in Q3 and Q2 ( computed as increase in GNPAs + Write Offs in the qtr vs avg AUM )

State wise branch count -

TN - 211

AP - 276

Telangana - 120

Karnataka - 62

MP - 111

Maharashtra - 40

Others - 24

Total branches @ 844 vs 748 @ end of FY 25

5 Star Business finance’s customers usually have lumpy cash flows. That’s the reason for optically higher stress in softer buckets ( 1 DPD+ and 30 DPD+ ). However, since their loans are secured in nature - their harder buckets ( GNPAs ) remain under control as the customers usually pay up. The business model is structurally different vs most other players. Even in Q4 FY 25, their 1 DPD + was @ 15.72 pc. However, in their best of times ie Q4 FY 24, 1 DPD+ was @ 12.61 pc

Notes from previous concalls -

Company is deliberately trying to lend more in 3-5 and 5-10 lakh ticket size bracket. They believe, the stress in this segment of customers is far lesser vs the customers with loan size < 3 lakh. Also as the cost of borrowing is falling and the company is also willing to lend at lower rates. The profile of customers that the company is getting ( incrementally ) is also improving. These ( supposedly ) better customers generally have ticket sizes > 3 lakh

Company’s avg customer has a CIBIL score profile of 500-550 or is completely new to credit vs bigger NBFC’s / Banks which lend to customers with CIBIL score > 700

End use of company’s loans include - Business loans ( 60 pc of loans ), construction related expenses or purchase of land ( 25 pc of loans ) , personal consumption like medial, educational etc ( 15 pc of loans )

Notes from Q4 Concall -

Aim to clock an AUM growth of 20 pc for FY 27 vs 11 pc AUM growth clocked in FY 26

Their 60 to 90 DPD bucket has come down from 5.1 pc in Q3 to 4.8 pc in Q4

Management is confident that the worst is clearly behind and are guiding for a much better performance going forward

Annualised credit cost for last 4 Qtrs ( Q4, Q3, Q2, Q1 ) has been - 1.88, 1.76, 1.60 and 1.58 pc respectively. Annual credit cost for FY 26 was @ 1.71 pc. Guiding for a credit cost of 1.7-1.75 for FY 27 and 1.5-1.6 pc thereafter

Guiding for RoAs @ 8.25 - 8.5 pc or thereabouts for FY 27

Spike in employee costs in FY 26 is also because the company has invested aggressively behind building / hiring more ppl towards their collection and legal teams

Company’s yeild in FY 27 should settle @ 22 pc - 22.25 pc or so

Company’s avg ticket size at the end of FY 26 is @ 4.2 lakh. Lending in 3-5 lakh is their sweet spot. It also keeps most of the competition away

The over leveraging and behavioural issues witnessed in last 12 - 15 months are now clearly receding

Company has also clearly bifurcated their Business and Collections verticals - to ensure improvements in asset quality

In company’s line of business, demand is never an issue. They just have to onboard the right customers

Confident of maintaining lower slippages and higher collections going forward - ensuring compression in GNPAs in FY 27

Aim to open another 70 branches in FY 27

Opex/AUM should be around 7-7.2 pc for next FY ( similar to FY 26 levels ) despite branches and headcount additions

Have added 224 branches + 4830 employees over last 2 Yrs taking the total branch and employee count to 844 and 14160. Clearly - they ve invested a lot in capacity building in last 2 yrs. Should start to see some benefits starting next FY

Company’s pricing is at the lower end of the range iro the customers that they r serving

Total write offs in FY 26 were @ aprox 165 cr

Company’s avg loan tenures are between 5-7 yrs

South : NonSouth AUM @ aprox 85:15. In FY 26, growth was led by non South Mkts. South Mkts should see meaningful growth rebound wef FY 27

Disc: hold a small tracking position, not SEBI registered, not a buy/sell recommendation, posted only for educational purposes

2 Likes

Maruti Suzuki -

Q4 and FY 26 results and concall highlights -

Q4 outcomes -

Revenues - 50078 vs 38839 cr, up 28 pc

EBITDA - 6156 vs 4842 cr, up 27 pc

Other income - 1583 vs 581 cr

PAT - 3590 vs 3857 cr, down 7 pc

Sales volume @ 6.76 vs 6.04 lakh vehicles, up 11.5 pc

Mini + Compact, UV segments grew by (-) 4 pc and 15 pc respectively. LCVs grew by 10 pc

FY 26 outcomes -

Revenues - 1.74 vs 1.45 lakh cr, up 20 pc

EBITDA - 21405 vs 20149 cr, up 7 pc

Other income - 4643 vs 5199 cr

PAT - 14454 vs 14296 cr, up 1 pc

Sales volumes @ 24.22 vs 22.34 lakh vehicles, up 8.5 pc

Mini + Compact segment, UVs grew by 3 pc and 6 pc respectively. LCVs grew by 12 pc

Apr 26 vs Apr 25 sales volume @ 2.39 vs 1.79 lakh vehicles - company is off to a very strong start in FY 27

Suzuki’s own Li-Ion battery manufacturing commenced in Q2 ( for their Hybrid Vehicles ) with cell and electrode level in-house manufacturing

Aim to launch 8 more SUVs in India by 2030

Notes from Q3 concall -

H1 and H2 volume growth in FY 26 stood @ (-) 5 pc and 12 pc respectively

1.9 lakh customer orders remain unserved as on 31 Mar. Out of these 1.3 lakh orders are in the small car segment. Dealer inventories are as low as 12 days of stock

Dzire was the best selling car in India in FY 26. Tata Nexon was No 2

Victoris was company’s fastest ever to 50k sales. However, company is now resorting to discounting in Victoris. Lets see how the future shapes up for this model

E Vitara was launched in India in Q4. Has been selling aprox 3k units / month ( 2k + 1k : domestic + exports )

Company’s share of exports from India is now @ 49 pc - a meaningful achievement

In Apr 26, company commissioned their second plant @ Kharkoda ( First plant @ Kharkoda was commissioned LY ). Also - 4th production line @ Hansalpur is slated to go live in current FY. Both these should add company’s production capacity by 5 lakh units / yr - this is a significant expansion

By 2030 or so - company intends to expand their production capacity to 40 lakh units / yr

FY 26 exports stood @ 4.47 lakh units

Company is now offering 6 airbags + ABS as standard features across their entire lineup

Have set up 2000 exclusive chargers across the country. Aim to ramp these upto 1 lakh chargers by 2030

In Q4, increase in GoI bond yeilds led to MTM hit of about 750 cr on the income from their surplus funds

Have declared a dividend of Rs 140 / share for FY 26

Demand sentiment continues to remain firm ( as of end of Apr, beginning of May ) - a key positive. There are some RM pressures due war in West Asia - but are not alarming in nature

The waiting list build up in Apr 26 is also because of company’s manufacturing capacity constraints

Expecting a 10 pc domestic volume growth for FY 2

First time buyers in Q4 were @ 51 pc. Repeat buyers were @ 18 pc. Rest were buying an additional car for their family. In H1, the ratio of first time buyers was @ 42 pc

Cash + Investments on books @ 78k cr

Capex lined up for FY 27 @ aprox 14k cr - towards capacity expansions @ Hansalpur + Kharkoda

Disc: hold a tracking position, biased, posted only for educational purposes, not SEBI registered

1 Like

Hero MotoCorp -

Q4 and FY 26 results and concall highlights -

Q4 Outcomes -

Revenues - 12797 cr, up 29 pc

EBITDA - 1856 cr, up 31 pc

PAT - 1401 cr, up 30 pc

Sales volumes @ 17.14 two wheelers, up 24 pc

FY 26 Outcomes -

Revenues - 46830 cr, up 15 pc

EBITDA - 6871 cr, up 17 pc

PAT - 5268 cr, up 14 pc

Sales volumes @ 64.69 lakh two wheelers, up 10 pc

Revenues from parts, accessories, merchandise for FY 26 stood @ 6147 cr, up 6 pc YoY

Consolidated PAT for FY 26 stood @ 5776 vs 4376 cr ( includes PAT contribution from Hero Fincorp )

Final dividend @ 75 / share. Total dividend @ 185 / share for FY 26

The year’s performance was anchored by consistent gains in the core ICE business, with Hero MotoCorp expanding its market share across key segments. Growth was broad-based across 100cc - 125cc, scooters and premium motorcycle segments, powered by a series of well-received product refreshes and the Company’s highest-ever festive season

VIDA, Hero MotoCorp’s Emerging Mobility Business, delivered a landmark year - reporting highest retail with record year-on-year growth of 190%, at 1.51 lakh units. The VIDA VX2 series successfully broadened the brand’s reach into the mass market, while the launch of DIRT.E K3 marked a significant milestone in VIDA’s purpose of reimagining the ‘Future of Mobility’ for a new generation

The Company’s Global Business closed FY’26 at an all-time high, with 40% year-on-year growth @ 4.03 lakh units, driven by consistent performance across key international markets. Hero MotoCorp expanded its global footprint to 52 countries with new market entries in Europe and the United Kingdom (UK), reinforcing its position as a truly global mobility brand. The Harley-Davidson Business also delivered 26% year-on-year growth in its dispatch volume. This strong performance was driven by the successful launch

Notes from Q4 concall -

Retail sales in FY 26 > primary sales leading to leaner inventory levels

Cash on books @ aprox 19k cr

Capex lined up for FY 27 @ 1500 cr - dedicated towards their ICE and EV scooters - both seeing strong demand momentum. Will also invest another 700 cr towards expanding their Parts / Accessories capacities

Adv and promotions were up 20 pc in FY 26 vs FY 25

Will be launching multiple new brands / variants in FY 26

ICE business’s EBITDA margins in FY 26 were @ 17.2 pc vs overall EBITDA margins of 14.7 pc - since EV business is presently a drag on profitability

Avg price hike in Q4 @ 3 pc

Facing commodity price hikes wef Mar 26 - should cause short term margin headwinds

Expecting, high single digit volume growth for FY 26 on a consol basis. Expecting double digit growth in scooters segment

Still in the phase of building out their EV portfolio. Will again be investing aggressively in this space in FY 27 as well. EBITDA losses / unit are inching downwards with increasing scale

Price hikes taken recently do not cover the commodity + energy price spikes that ve happened recently

Have increased Destini ICE scooter’s capacity by 50 pc - recently. Will be increasing EV scooters and Xoom ICE scooters capacity by 100 pc in FY 27

ICE Scooters, EVs, Ather’ portfolio, ICE exports - all four are key focus areas for the company going forward

In Q4, Company was able to sell 5200 units of X440 - Harley bikes in India. Need to monitor progress of this JV

Lower base in H1 FY 27 is a tailwind for the company

Commodity price hikes in Q4 are @ aprox 2k / unit

Dealer level inventories stand @ around 5 weeks

Exports revenues in FY 26 @ 3500 cr

Company’s stake in Ather is now @ 37 pc

Disc: holding, biased, not SEBI registered, posted only for educational purposes

1 Like

Wonderla Holidays -

Q4 and FY 26 results and concall highlights -

Q4 outcomes -

Revenues - 142 vs 107 cr, up 32 pc

EBITDA - 50 vs 30 cr, up 64 pc

PAT - 16.4 vs 11 cr, up 49 pc ( due increased depreciation @ 28 vs 16 cr, due operationalisation of Chennai park )

Total footfalls @ 8.79 vs 6.78 lakh, up 30 pc

Avg ticket price @ Rs 999, up 6 pc

ARPU @ Rs 1456, up 7 pc

Park wise revenues -

Bengaluru - 35 cr, up 7 pc

Kochi - 29 cr, up 9 pc

Hyderabad - 30 cr, up 3 pc

Bhubneshwar - 5.3 cr, up 13 pc

Chennai - 29 cr vs NIL

Resorts - 7 cr, up 84 pc. Occupancy @ 56 vs 43 pc

FY 26 outcomes -

Revenues - 551 vs 482 cr, up 14 pc

EBITDA - 192 vs 171 cr, up 12 pc

PAT - 82 vs 109 cr, down 25 pc ( full yr depreciation @ 83 vs 57 cr - due operationalisation of Chennai Park )

Footfalls - 32.19 lakh, up 6 pc

Avg Ticket price @ Rs 1061, up 4 pc

ARPU @ Rs 1530

Park wise revenues -

Bengaluru - 173 cr, up 3 pc

Kochi - 123 cr, up 2 pc

Hyderabad - 132 cr, up 3 pc

Bhubneshwar - 53 cr, up 13 pc

Chennai - 41 cr vs NIL ( went live in late Q3 )

Resorts - 26 cr, up 56 pc. Occupancy @ 53 vs 49 pc

Facilities operated by the company -

5 Amusement parks ( Chennai park opened in Q3 )

230 Rides

23 restaurants

5 Banquet halls

7 Food courts

3 Lounge Bars

2 Resorts

Notes form previous Concalls -

Chennai Park’s peak capacity stands @ 10-12 lakh visitors / yr. ( Assumption : That should translate into a peak revenue potential of aprox 213 cr @ an ARPU of Rs 1800 ). Company is hopeful of achieving this inside 3-4 yrs

Aprox 35-40 pc land is still un-utilised @ their parks in Kochi and Bengaluru. This figure for Hyderabad park is aprox 25 pc. Company keeps slowly adding newer attractions, restaurants, rides, resorts etc @ these available land banks

Qtrly operating costs ( without depreciation ) for Chennai park should be around Rs 9 - 10 cr / qtr

In peak seasons ( in Q1 ), company has to ( by force ) leave some demand on the table as they do not overcrowd their parks. Hence they also keep undertaking gradual expansion like adding rides etc

As a fair assumption, one can factor in 1 new large park commercialisation by the company in next 3 yrs

Expect Chennai to clock > 20 pc EBITDA margins in FY 27 and then build up thereafter

Notes from Q4 Concall -

No large capex planned for FY 27

Company hopes, their Chennai park achieves financial matrices comparable to that of Bengaluru park

Hopeful of finalising a deal for their 6th park in FY 27. Cash on books shall be utilised to fund that capex. Its just that large RE deals take time to materialise

Should open a min of 3 more parks in next 5 yrs

Seeing descent demand trends in Q1

Yearly depreciation wrt Chennai park for FY 27 should be 45-50 cr

Company has re-caliberated its strategy to go for larger format parks near Tier - 1 locations vs smaller sized parks near Tier - 2 locations. Hence - it’s taking more time ( more than usual ) to finalise the location for their 6th park as land parcels are more difficult to acquire near Tier 1 locations. Currently in active discussions with 4 state Govts

Chennai park clocked EBITDA margins of 30 pc in Q4. Q1 should be even better - its the peak season with summer vacations

Bhubneshwar park clocked footfalls of aprox 2 lakh in FY 26. In medium term, aim to reach annual footfalls of > 3 lakh @ Bhubneshwar. That would significantly improve the park’s return ratios

Non Ticket revenues have a far higher potential for growth vs the ticket revenues. In developed countries, on ticket revenues are generally 2X of ticket revenues. Company hopes to clock 50:50 - ticket:non ticket revenues in medium term

Don’t have a blanket liquor license. Do take it for special events. Don’t want to serve it under normal circumstances as its more a family outing oriented business

Disc: hold a small position, inclined to add more, not SEBI registered, biased, not a buy/sell recommendation, posted for educational purposes only

1 Like

Orient Electric -

Q4 and FY 26 results and concall highlights -

Q4 outcomes -

Revenues - 948 cr, up 10 pc

GMs @ 31 pc, down 47 bps

EBITDA - 77 cr, up 16 pc ( margins @ 8.2 vs 7.8 pc )

PAT - 40 cr, up 33 pc ( due lower depreciation, interest costs )

Segmental performance -

ECDs -

Revenues @ 661 cr, up 7 pc

EBIT- 75 vs 68 cr, up 10 pc

States where company has DTM distribution grew in double digits driven by strong execution

35 pc of fan sales now come from premium categories

Took an avg price hike of 4 pc in Q4

Fan exports also grew in double digits

Lighting and Switchgears -

Revenues - 287 vs 248 cr, up 16 pc

EBIT - 40 vs 31 cr, up 32 pc ( led by margin expansion @ 14.1 vs 12.5 pc )

Strong growth witnessed in Switchgears + Wires

Margin expansion led by higher share of premium lighting products

B2C lighting grew in double digits

Launched decorative lighting in Q4

FY 26 outcomes -

Revenues - 3326 cr, up 7.5 pc

EBITDA - 229 vs 203 cr, up 12.5 pc ( margins @ 6.9 vs 6.6 pc )

PAT - 96 vs 83 cr, up 15 pc

Notes from previous Concalls -

Company has rolled out its wires portfolio in North and East India. They ll improve the depth and breadth ( new geographies ) of their distribution in a calibrated manner. Company’s strong distribution in fans should be a natural tailwind for their Wires business

Company believes - they should reach 10 pc kind of EBITDA margins towards the end of FY 27 ( in line with other FMEG players ) - this can be a big kicker for the bottomline going forward

Wires and Switch Gears have a low base, but is a future growth engine for the company

BLDC fan’s profitability is > non BLDC fans

B2B:B2C spit in lighting sales for the company stands @ 75:25. Industry norm is around 65:35. Company is working hard to move in that direction

Keeping a razor sharp focus on premiumisation. It also helps margins in a big way as customers at premium end of the mkt are not very price sensitive

A&P as a percentage of sales stood @ an elevated 4.5-5 pc ( as the company is working on new categories )

Notes from Q4 concall -

Share of premium lighting @ 68 pc now - margin accretive

BLDC fans now contribute to 25 pc of company’s fan sales - again margin accretive

SANCHAY program ( their cost cutting initiative ) helped them save 68 cr in FY 26 - supporting their margins

Expecting better demand trends in Q1 - on the back of better summers vs LY when they were exceptionally weak

Have hiked prices by another 6 pc across their portfolio in Q1 - due steep commodity price hikes

Grew their Heating appliances + Irons business in double digits in FY 26

GMs in Q4 were adversely affected by 1-1.5 pc due delayed price hikes + steep commodity inflation seen after the war broke out in late Feb

Company’s TPW fan manufacturing capacities are located @ Kolkata and Hyderabad. Both these are ideal location for the company to target Southern India + Export mkts

About 45 pc of secondary Fan sales in India happen in Q1 and the rest 55 pc in the next 3 Qtrs combined

H1 FY 26 was very sluggish for the company - due weak summers LY. Summers this year have been near normal, till now

Disc: hold a small position, biased, posted for educational purposes, not SEBI registered

Karur Vysya Bank -

Q4 and FY 26 results and concall highlights -

Q4 outcomes -

NII - 1359 cr, up 25 pc

Fee income - 280 cr, up 6 pc

Other income - 336 cr, up 37 pc

Total income - 1975 cr, up 24 pc

Operating expenses - 728 cr, down 5 pc

Operating profit - 1247 cr, up 49 pc

Provisions - 258 cr, pp 59 pc

PAT - 725 cr, up 41 pc

RoA - 2.1 pc

RoE - 20.55 pc

NIMs - 4.25 pc

Cost / Income - 37 pc ( very healthy levels for a commercial bank )

Avg yeild on advances - 9.93 pc

Yield on funds - 8.92 pc

Cost of funds - 5.38 pc

Cost of deposits - 5.41 pc

Advances @ 98.7 k cr, up 17 pc

Deposits @ 115.6 k cr, up 13

CASA @ 31.1 k cr, up 12 pc

GNPAs @ 0.75 pc

NNPAs @ 0.19 pc

PCR @ 96.45 pc

FY 26 outcomes -

NII - 4939 cr, up 16 pc

Fee - 1050 cr, up 9 pc

Other income - 1034 cr, up 20 pc

Total income - 7023 cr, up 15 pc

Total expenses - 2948 cr, up 2 pc

Operating profits - 4075 cr, up 27 pc

Provisions - 755 cr, up 22 pc

PAT - 2510 cr, up 29 pc

Breakdown of Advances -

Commercial banking - 34.3 k cr, up 12 pc

Retail banking - 26.2 k cr, up 25 pc

Agri - 24.8 k cr, up 19 pc

Corporate banking - 13.5 k cr, up 12 pc

Credit substitutes - 1.11 k vs 0.14 k cr

RAM (Retail + Agri + Commercial ) verticals now constitute 86 pc of company’s advances vs 77 pc @ the end of FY 23

Growth in retail vertical led by LAP, Gold loans - both these segments grew @ > 50 pc in FY 26

Avg ticket size of company’s advances in commercial segment @ 55 lakh. 67 pc of commercial loans are less than 5 cr in value

Agri + Non Agri Jewel loans @ 22.7 k + 6.7 k = 29.5 k cr - representing 30 pc of company’s total loan book

Total branches now @ 901. Opened 13 branches in FY 26 and 50 branches in FY 25

Avg ticket size in corporate loans @ 36 cr. 97 pc of corporate loans are to parties with rating @ BB and better

Unsecured loans @ 1.9 pc of the total loans. Despite this, Bank is able to clock such healthy NIMs

India US trade deal + India EU FTAs are key positives going forward for the textiles sector - another positive for the bank ( LY - it was a hangover- on account of high tariff rates )

Since the bank’s loan book is so secured in nature, the recoveries vs slippages ratio is always healthy - reducing the pressure on asset quality

Notes form Q4 concall -

Deliberately reduced / held back on advances growth in Q4 due volatile geopolitical scenario

BNPL products witnessed a 2 pc de-growth in FY 26 - a deliberate strategy in times of elevated household leverage. Now turning positive on this segment - should report descent growth in BNPL in FY 27

91 pc all agri loans are given out against gold as collateral

MFI + BNPL portfolio @ 1.5 pc of company’s loan book

Housing loans grew in low single digits in FY 26 - due steep competition / pricing pressures

Appointed 100 relationship managers to develop and drive new MSME relationships

CASA deposits grew by 12 pc in FY 26 over FY 25

Closed FY 26 with NIMs of 3.97 for full FY 26

Breakup of loan book wrt rates -

Fixed rate loans @ 29 pc

MCLR book @ 14 pc

EBLR book @ 55 pc

Provisions maintained by the bank including - standard + floating + restructured + against NPAs + prudential = 1747 cr = 1.77 pc of company’s advances. This is against GNPAs of 0.75 pc !!!

Total restructured loans @ 403 cr = 0.41 pc of loan book

Won’t need to raise money for FY 27 due healthy generation of PAT of 2510 cr

Aim to keep growing 2 pc above Industry’s advances growth

Should launch loans against MFs in H1 FY 27

Aim to ramp up corporate share of advances to 20 pc - seeking opportunities in that segment

Guiding for NIMs of 3.75 to 3.8 pc for full FY 27 - due upward pressures on deposit rates and downward pressures on lending rates

Aim to aim 50 branches in FY 27 - mostly in H1

Credit growth is not an issue at all. Key is to be able to raise deposits @ low enough rates and lend at remunerative rates

Blended yeild on gold loans @ around 11 pc ( agri + retail gold loans ) - imo, going forward - this can be a key growth area for the bank

Bank believes, they ll have to make some compromises on cost of lending - in order to keep / retain their best customers, as the competition from other Pvt / PSU banks is high. Hence the conservative guidance that they ve given on NIMs for next FY

Despite the relief on tariffs, stress in textiles sector is not yet over. Watching this space closely. Hoping for a favourable resolution

Total recoveries in FY 26 stood @ 670 cr - very healthy numbers

If company reduces its lending rate from 11 to 9.5 pc ( aprox ) on gold loans, they can unleash a lot of growth in this segment. They can literally take the Gold loan portion of their book from 29 pc to 40 pc in a short period of time. However, they r not compromising on margins - at the moment. Hence not doing it. Even without this, Gold may still end up being 35 pc of their loan book in medium term

Disc: holding, investment position, not SEBI registered, posted only for educational purposes

1 Like

Bajaj Auto -

Q4 and FY 26 results and concall highlights -

Q4 outcomes -

Revenues - 17.83 vs 12.64 k cr

EBITDA - 3075 vs 2358 cr ( margins @ 17 vs 19 pc )

Other income - 1894 vs 392 cr

PAT - 3492 vs 1802 cr

Q4 sales volumes -

Domestic -

2Ws - 6.21 vs 5.01 lakh, up 24 pc

CVs - 1.38 vs 1.12 lakh, up 24 pc

Exports -

2Ws - 5.44 vs 4.42 lakh, up 23 pc

CVs - 65k vs 47k, up 39 pc

KTM + Triumph sales in domestic mkt grew by 40 pc on a YoY basis

FY 26 outcomes -

Revenues - 62.9 vs 50.9 k cr

EBITDA - 13.06 vs 9.55 k cr

Other income - 2.7 vs 1.4 k cr

PAT 10.57 vs 7.32 k cr, up 46 pc

FY 26 sales volumes -

Domestic -

2Ws - 23.49 vs 23.08 lakh, up 2 pc

CVs - 5.18 vs 4.78 lakh, up 8 pc

Exports -

2Ws - 19.67 vs 16.74 lakh, up 18 pc

CVs - 2.82 vs 1.89 lakh, up 49 pc

Bajaj Auto Credit reported an AUM growth of over 2X to 18.83 k cr. Reported a PAT of 665 cr vs 58 cr in FY 25. Its NNPAs and RoE stood @ <1 pc and 23 pc respectively

In Q4 FY 26, company has recorded 1195 cr as a share of its profit ( from their 75 pc holding in Bajaj Auto International Holdings BV ) - mostly due re measurement of investments on the BS of Bajaj Auto ( ie 49 pc stake in PBAG ) on the date of acquisition + Fx currency transaction gains

Notes from Q4 concall -

Exports crossed 6 k units in Q4 - for the second time after Q3. Achieved this despite Nigeria volumes being @ 50 pc of their normal levels

LATAM has reported 11 th straight Qtr of YoY growth

KTM motorcycle exports revived in Q4 - touching 17.5k units vs NIL in Q4 LY - due problems @ their erstwhile parent company

Pulsar exports continued to remain very strong

Bajaj Auto is now no-5 2W company in Brazil clocking qtly sales volumes of aprox 10k units with 70 sale touch points

Pulsar N and NS series have been growing @ 2X the Industry growth in India for last 4 months now

KTM + Triumph sales in Q4 stood @ 43k units - a very promising outcome for the company

KTM and Triumph’s growth are led by Duke 250 and Speed 400

Have launched 350 cc Triumphs and KTMs - should see further volume gains in Q1. Have opened 90 joint - Triumph + KTM stores in India

Chetak clocked 1 lakh units in Q4 - is now no 2 after TVS I Qube. Chetak revenues clocked 4k cr in FY 26

April sales data continues to be extremely strong -

Domestic -

2Ws - 2.1 lakh, up 11 pc

CVs - 38 k, up 19 pc

Exports -

2Ws - 2.29 lakh, up 78 pc !!!

CVs - 35 k, up 125 pc !!!

Grand total for Apr 26 - 5.13 lakh, up 40 pc

Commenced Chetak’s exports to SL, Nepal and Philippines in Q4

Company’s CNG share in 3Ws @ > 90 pc ( in domestic mkts )

Have regained no 1 spot in E 3Ws in domestic mkts in Q4 ( in volume terms )

Launched Bajaj WEGO - largest electric 3W in the Industry in Q4

Have taken price hikes wef 1 Apr - to counter the RM inflation - both in rare earth and base metals

Rupee depreciation helped them extract better export realisations - helping margins

Revenues from spares are now clocking a stable run rate of 1700 - 1800 cr / Qtr, providing a recurring support to company’s overall revenues and margins

Company’s EV portfolio ( CVs + Chetak ) clocked double digit EBITDA margins for FY 26

Cash on books @ 18k cr

Have declared a dividend of Rs 150 / share + Rs 5600 cr share buyback @ Rs 12k / share - to celebrate Bajaj group’s 100 yrs since formation

Electric 3Ws are seeing very strong demand trends - offsetting demand slack in ICE 3Ws

Demand trends in LATAM are holding up in a firm manner

Company’s mkt share in Nigeria is @ 50 pc - a big achievement

Dominar continues to do really well in LatAm ( selling much more than India sales ). Company believes that Dominar is an under leveraged brand in India. Can do much more with this brand in India

Company’s mkts like Mexico, Argentina, Peru, Columbia - also continue to do well

Have ramped up Chetak’s manufacturing capacities to 50k units / month. Hopeful of being able to sell 100 pc of this in FY 27 - vs a run rate of around 30k / month towards the end of FY 26

Plan to launch a bunch of new products - within the Pulsar brand wef July. Will also be launching a new brand in 125 cc category

EBITDA margins for Chetak servies have been at break even levels. Despite this, 3W + 2 W combined EV portfolio is clocking double digit EBITDA

Have opened high end / exclusive kind of stores in Brazil - only pushing brands like Pulsar and Dominar. Following a top - down approach in Brazil, where in they r focusing more on the brand and currently not going after volumes

Have lost export sales of around 5-6k units / month to ME for months of Mar/Apr 26

Off late, 3Ws ( ICE + EVs ) have been the fastest growing category in India among Auto categories. This is driven by the exploding demand for last mile connectivity - a structural positive for the company. Most of this growth is driven by larger format 3Ws

Seeing sharp commodity price inflation. If measured from Q4’s steady state, gross margins in Q1 would be hit by 400 bps - due RM inflation. Have taken price hikes to mitigate 40 pc of the RM inflation impact wef Apr. May resort to another round of price hike going forward

Disc: hold a small position, inclined to add on dips, not SEBI registered, not a buy/sell recommendation, posted only for educational purposes

2 Likes

NALCO -

Q4 and FY 26 highlights -

Q4 outcomes -

Revenues - 4981 cr, down 5 pc

EBITDA - 2547 cr, down 12 pc

PAT - 1718 cr, down 17 pc

Q4 physical performance -

Alumina exports - 3 lakh MT

Alumina domestic sales - 38k MT

Aluminium exports - 6.11k MT

Aluminium domestic - 1.16 lakh MT

FY 26 outcomes -

Revenues - 17729 cr, up 6 pc

EBITDA - 8613 cr, up 8 pc

PAT - 5813 cr, up 9 pc

Alumina sales ( exports + domestic ) - 14.46 lakh MT

Aluminium exports - 13k MT

Aluminium sales - 4.61 lakh MT

FY 26 physical performance -

LME prices for aluminium averaged around $ 3150 / ton in FY 26. Today’s prices are @ 3550 / ton

NALCO is an integrated Bauxite - Alumina - Aluminium -Coal - Power company. It is the global leader in producing bauxite and alumina at the lowest cost

Top 6 user Industries of aluminium -

Electrical

Transportation and Automobiles

Building and construction

Consumer durables

Machinery and Equipment

Packaging

Company expects the demand for aluminium in India to keep growing @ 6-7 pc CAGR for next 5 yrs

Existing facilities and Ongoing expansion projects -

Bauxite - 7.5 million MTPA ( located @ Panchpatmali, Odhisa ) - total reported resources @ 310 million MT

Expansion underway @ Pottangi Bauxite mines ( located @ a distance of 25 km from Panchpatmali ). It ll have a capacity of 3.5 MTPA with reserves of 110 million Tons. Expected to be commissioned in May 26

Alumina Refinery - 2.1 million MTPA ( producing alumina hydrate, special hydrates, Calcinated alumina ) - located @ Damajodi ( Odisha ) - aprox 14 km away from Panchpatmali. The mined-out bauxite is transported from captive mine to refinery by a 14.6 KM long single-light multi-curve 1800 tonnes per hour (TPH) capacity cable belt conveyor

Expansion is currently underway at the Alumina refinery. Capacity is expected to go up by 1 MTPA. Expected to be commissioned in Jun 26

Aluminium Smelter - 0.46 million MTPA ( producing Aluminium metal - Ingots, Billets, Wire Rods, Rolled products ) - located @ Angul ( Odisha ). The alumina produced is transported to aluminium smelter at Angul (Odisha) and to Vizag ( for exports ) port by rail

Smelter expansion shall double the company’s refined aluminium’s capacities. Likely to be commissioned in Dec 30

Captive coal mines - 4 million MTPA ( @ At Utkal coal mines in Angul district )

Company can increase its Coal block’s production by 20 pc above 4 million MTA without environmental clearances

Captive thermal power capacities @ 1200 MW ( 10 X 120 MW ) located @ Angul

Additional captive power plant with capacity of 1080 MW - expected to go live in FY 31

Wind power capacities @ 198 MW

Capex for company’s Aluminium Smelter shall begin in FY 28. For Smelter, the capex should be around 17000 cr. For 1080 MW power plant, capex requirement should be around 13000 cr

Notes from previous concalls -

KABIL JV ( between Nalco : Hind Copper : Mineral exploration and consultancy limited in the ratio 40 : 30 : 30 ) has 5 mines in Argentina ( Lithium mines ). Non invasive exploration is complete. Results were encouraging. Commercial mining may take > 2 yrs to begin ( once they ascertain commercial viability for which they ll take another 6 months )

Capex for Alumina refinery expansion has been around 4000 cr. Should spend another 1300 cr before the refinery goes live. Should be able to make Rs 10000 / MT ( aprox $ 109 / ton ) kind of margins ( post depreciation ) from this new refinery ( even at depressed alumina price levels )

Should be able to produce additional 2 lakh MT of Alumina in FY 27 and 10 lakh tons ( full ramp up ) by FY 28 - from the new refinery. This should add another 200 cr / 1000 cr to company’s EBITDA over FY 27 / FY 28

2-3 new Alumina refineries have come up in Indonesia + 1-2 smelters have been shut in China and elsewhere. That’s why Alumina prices r weak but aluminium prices continue to rise

2-3 new Alumina refineries have come up in Indonesia + 1-2 smelters have been shut in China and elsewhere. That’s why Alumina prices r weak but aluminium prices continue to rise

In talks with two companies to form JVs for extraction of rare earth minerals from Alumina Red Mud. Aprox 1-1.5 tons of Red mud is generated / 1 ton Alumina production

Also forming a JV with another company for extraction of Gallium from Liquid Residual of Alumina production

Aluminium cost of production in Q4 is running @ aprox $ 1750 / ton

1.93 tons of Alumina are required to produce 1 ton of Aluminium

In Q3 - Company’s avg selling premium in domestic mkt ( over LME prices ) was aprox $ 28

CP Coke ( calcinated petroleum coke ) is used as Anode in Aluminium Smelters

Notes from Q4 concall -

Alumina realisations @ $ 370 vs $ 580 / ton in FY 26 vs FY 25 - steep fall in realisations

Aluminium realisations @ $ 2700 vs $ 2550 / ton in FY 26 vs FY 25 - descent gain in avg realisations wrt metal. Current metal price is very healthy @ > $ 3550 / Ton

Alumina production target for next FY @ 2.5 million MT, Aluminium @ 0.47 lakh MT

Alumina exports directed to ME was aprox 40 pc of company’s Toal exports pre - Iran war. Since those supplies are now under pressure, spot Alumina prices have now fallen further to $ 310 / Ton. Aiming to make up for the lost Alumina sales from sales to other geographies + domestic sales. A key advantage that NALCO enjoys is that the quality of its Bauxite mines is rich. Because of which, they enjoy a benefit of $ 100 / Ton in Alumina and $ 200 / Aluminium production

Alumina realisations in Q4 were @ $ 348 / Ton. As of end Apr, they r selling Alumina @ $ 310 / Ton

Capex tgts for FY 27, 28, 29 - should be around 1.8k, 4k and 8k cr

Company’s avg cost of production for Alumina is around $ 230 / Ton

Assuming avg Aluminium and Alumina prices @ $ 3350 and $ 320 + Avg Aluminium and Alumina sales @ 4.7 lakh and 15 lakh tons - Revenue from Aluminium and Alumina sales for FY 27 should be around 14.9 k cr + 4.5k cr = 19.5 k cr. These figures for FY 26 were @ 12k cr + 5k cr = 17 k cr - these r optimistic assumptions :grimacing:

Next yr, their employee costs should be lower - as fresh hirings are < superannuations + the Superannuating employees draw greater salaries

Capex incurred in FY 26 was @ 2000 cr

Alumina surplus should continue in FY 27 as well. So the prices should naturally remain under pressure

Company’s annual requirement vs captive production of coal in FY 26 stood @ 7.2 million tons vs 4.2 million tons. They aim to ramp up captive production to 4.8 million tons in FY 27

Company has a JV with GACL to produce caustic soda. half of their caustic soda requirements are met by the production from that JV. Aprox 200 kg of caustic soda is required for 1 MT production of aluminium

Caustic soda prices are up 7-8 pc in last 4-6 months

Cash on books @ aprox 8.5k cr

Management believes, $ 300-310 / Ton should be the floor for Alumina prices

Will be adding brownfield capacity to their flat rolled + wire rod products ( subsumed in their capex guidance ). Its a profitable business area for them

Employee costs should see an avg hike of 12-14 pc in FY 28 - on account of implementation of new pay commission

In talks with Neyveli Lignite to form a 50:50 JV - to share the capex for the proposed power plant to be built along with the new Aluminium smelter. Talks are in advanced stages. Should be a sweet deal for Neyveli as they have Lignite mines in nearby areas

The royalty that the company pays on Bauxite mining depends on the LME prices. Hence continues to vary all the time

For FY 26, ratio of revenues from Aluminium : Alumina was @ 73 : 27. Fall in Alumina prices is being more than offset by gains in Aluminium prices

Their JV with GACL produced a negative EBITDA of 30 cr. This FY, it should make a positive EBITDA

Disc: hold a small trading position, not SEBI registered, posted only for educational purposes, biased

1 Like

Innova Captab -

Q4 and FY 26 results and concall highlights -

Q4 outcomes -

Revenues - 447 vs 314 cr, up 42 pc

EBITDA - 67 vs 51 cr, up 31 pc ( margins @ 14.9 vs 15.4 pc )

PAT - 38 vs 30 cr, up 29 pc

Segmental revenues -

CMO - 314 vs 223 cr, up 40 pc

Branded generics - 133 vs 91 cr, up 46 pc

FY 26 outcomes -

Revenues - 1630 vs 1243 cr, up 31 pc

EBITDA - 250 vs 198 cr, up 26 pc ( margins @ 15.4 vs 16 pc )

PAT - 141 vs 128 cr, up 10 pc. Yearly depreciation charges @ 45 vs 28 cr - due operationalisation of new Jammu facility

Segmental revenues -

CMO - 1133 vs 915 cr, up 23 pc

Branded generics - 496 vs 328 cr, up 51 pc

Manufacturing facilities -

Baddi - 3 blocks - Tablets, Capsules, Dry syrups, Oral Liquids, Ointments, Dry powder injectables

Jammu - 4 blocks - Tablets, Capsules, Dry syrups, Respules, Parenterals, Dry powder injectables

Dehradun - 1 block - Tablets, Capsules

Taloja - 1 block ( API facility )

Company is eligible for GST benefits totalling upto 300 pc of investment made in Jammu plant + Interest rate subvention upto 6 pc

Jammu plant has a peak revenue potential of 1400 cr

CMO facilities often peak out @ 70-75 pc capacity utilisation levels. That means the existing plants ( Ex - Jammu ) have an additional revenue potential of 15 - 20 pc

Notes from Q4 concall -

Company’s Cephalosporin facility @ Baddi received UK MHRA certification in last FY

Several marquee customers successfully conducted quality and compliance audit @ their Jammu facility

Expecting revenue growth to be > 20 pc and EBITDA growth to be higher than revenue growth in FY 27 - as further ramp up related benefits from their Jammu facility start to flow through. Most of the fixed costs related to operating the Jammu facility are already in the base

Seeing increased API prices. Should be able to pass them on to their customers

Both - company’s CMO and Branded business have a roughly 70;30 split between domestic : export sales ( ie for last FY )

Should see EBITDA margin expansion FY 26. However, they did not quantify the same

For full FY 26, Jammu facility clocked revenues of 300 cr. From Q1, Jammu facility should start to contribute positively to absolute EBITDA. In Q4, it operated at breakeven margins

At present, seeing a meaningful increase in API prices of Cephalosporins

Ex - Jammu, company is operating an EBITDA margins of 18-18.5 pc - very healthy levels - for a formulations CMO player

Have purchased a new land parcel worth 20 cr @ Baddi - intent is to go for a brownfield expansion, since the Baddi plant is running at higher capacity utilisations

Capital outlay for this expansion @ Baddi should be around 170 cr. Bulk of this shall be spent in FY 28. This new block should have an yearly revenue potential of 450-500 cr

Sharon Bio ( acquired 2 yrs ago ) - mostly caters to regulated export mkts. They clocked revenues of 240 cr in FY 26 with margins better than Innova’s consol EBITDA margins

Expecting Jammu plant to clock revenues of > 450 cr in FY 27 ( a reverse calculation based on management’s comments )

Their domestic branded business is basically a trade generics business. They do not generate prescription sales

Disc: hold a small position, not SEBI registered, posted only for educational purposes

2 Likes

Aditya Vision -

Q4 and FY 26 results and concall highlights -

Q4 outcomes -

Revenues - 625 vs 487 cr, up 28 pc

EBITDA - 51 vs 42 cr, up 19 pc ( margins @ 8.1 vs 8.7 pc )

PAT - 31 vs 24 cr, up 27 pc

Q4 revenues have been positively impacted by an early onset of summer in Q4 vs LY

FY 26 outcomes -

Revenues - 2672 vs 2260 cr, up 18 pc

EBITDA - 228 vs 204 cr, up 12 pc ( margins @ 8.5 vs 9 pc )

PAT - 158 vs 143 cr, up 11 pc

Total store count now @ 207 stores vs 175 stores as on 31 Mar 25

Product mix -

Large appliances - 60 pc

Digital gadgets - 24 pc

Smaller appliances - 16 pc

No of stores opened in last 3 yrs @ - 40 + 30 + 32 = 102 stores, taking the total store count up from 105 to 207 stores

State wise breakup of stores -

Bihar - 118

Jharkhand - 33

UP - 53

Chattisharh - 3 ( entered this mkt in FY 26 )

MP - entry planned in FY 27

Company’s cost structure -

GMs @ 15.6 pc

Employee costs @ 3.1 pc

Rent @ 2.1 pc

Adv and Promos - 1.1 pc

Electricity - 0.9 pc

Misc - 1.4 pc

EBITDA @ 8.7 pc

Notes form Q4 concall -

Were able to grow revenues and PAT @ 18 and 11 pc respectively - despite witnessing the weakest summer since their inception

H1:H2 revenues now @ 53:47 - reducing business seasonality in a significantly manner

Have on-boarded Mr Pankaj Tripathi as their brand ambassador

SSSG in FY 26 @ 8 pc. SSSG in Q4 stood @ 18 pc

Bihar:UP:Jharkhand revenue breakup @ 74:14:12

Are adequately stocked for Q1 - so as to ensure they get best deals from OEMs in order to sustain and expand GMs

As their new stores improve their profitability, their EBITDA margins should inch upwards ( as most of the expansion has happened in last 3 yrs )

Mobiles + Laptops have lower margins vs Large + Small appliances

Other expenses were elevated in FY 26 due expansion push undertaken in UP

They do not divulge their state wise margins. Hopeful of bringing UP and Jharkhand upto Bihar levels over medium term

Should open > 30 stores / yr for next 2-3 yrs

April 26 sales were very strong. Beginning of May has been relatively soft

Disc: hold an investment position, not SEBI registered, biased, posted only for educational purposes, not a buy/sell recommendation

1 Like

Kamat Hotels -

Q4 and FY 26 results and concall highlights -

No of operational Hotels -

Orchid ( premium ) - 10

Heritage Hotels ( premium ) - 3 ( Madhodhani + Jadavgarh + Toyam )

IRA ( mid premium ) - 8

Lotus ( mid premium ) - 2

Ownership status of Hotels -

Owned hotels - 02. These are - Orchid Mumbai and Orchid Goa

Leased hotels @ 13

Managed hotels @ 4

Revenue share hotels @ 4

Upcoming properties in 2026 -

Orchid Gwalior - Sep 26

Orchid Dehradun - Sep 26

IRA - Bhavnagar - May 26

Orchid - Nahsik - Sep 26

Orchid - Nahsik will be a managed property. Others are leased properties

Orchid Mumbai and Pune with 370 and 410 rooms are their biggest properties

Hotels operationalised in FY 26 included -

Orchid - Chandigarh, Panchgani, Rishikesh

IRA - Hyderabad, Dwarka, Porvorim ( North Goa )

Have added Banquets halls, upgraded all rooms, built additional 25 rooms @ Pune Hotel. Should go live next year and company should reap financial benefits on FY 27. An additional wing of rooms is also going to be added @ their Noida hotel - early next yr

Q4 outcomes -

Revenues - 110 vs 92 cr, up 19 pc

EBITDA - 32 vs 25 cr, up 28 pc

PAT - 17.5 vs 11 cr, up 59 pc

FY 26 outcomes -

Revenues - 385 vs 357 cr, up 8 pc

EBITDA - 97 vs 104 cr, down 8 pc

PAT - 38 vs 47 cr, down 17 pc

Brand wise ARRs for FY 26 -

Orchid - 6393

IRA - 5292

Lotus - 5912

Heritage - 8920

Brand wise Occupancies for FY 26 -

Orchid - 54 pc

IRA - 69 pc

Lotus - 58 pc

Heritage - 30 pc

Notes from Q4 concall -

MMR region continues to witness good demand trends. Opening of Navi Mumbai airport, other infra buildup in the city is a key positive

IRA @ Bhavnagar is expected to open in June. Orchid @ Gwalior, Dehradun, Nahsik - witnessing delays due steep hike in construction costs + non availability of key RMs

Their new Hotels @ Rishikesh, Porvorim, Chandigarh are now doing well

Barring external shocks - should see margin expansion in FY 27 vs 26 ( as 6 newly opened ramp up their occupancy )

Orchid is a popular choice for Akasa, Indigo airlines - for their staff’s stop overs

IRA Mumbai - now stands closed due expiry of lease and its non renewal

Should see much better occupancy @ Fort Jadavgarh hotel. Have taken a number of corrective initiatives to reverse the situation

Witnessing higher manpower costs - also attributable to implementation of new wage code + opening of 6 new hotels in FY 26. As these properties ramp up, better cost absorption should happen in next FY

Current RoI that they r paying on their Debt of aprox 90 cr is 9.75 pc. Cash on books @ aprox 40 cr

Disc: hold a small position, not SEBI registered, posted only for educational purposes, biased

1 Like

Park Medi World -

Q4 and FY 26 results and concall highlights -

Q4 outcomes -

Revenues - 460 vs 360 cr, up 30 pc

EBITDA - 127 vs 88 cr, up 44 pc ( margins @ 27.7 vs 25 pc - descent margin expansion )

PAT - 77 vs 52 cr, up 47 pc

OPD volumes @ 1.88 vs 1.67 lakh patients

IPD volumes @ 0.25 vs 0.16 lakh patients

FY 26 outcomes -

Revenues - 1679 vs 1393 cr, up 21 pc

EBITDA - 444 vs 371 cr, up 20 pc ( margins flat @ 26.5 pc )

PAT - 276 vs 215 cr, up 27 pc

Total bed capacity @ 3610 vs 3000 beds as on 31 Mar 25, up by 20 pc

OPD volumes @ 7.78 vs 6.38 lakh patients

IPD volumes @ 0.96 vs 0.81 lakh patients

Company’s existing hospitals are located @

Mohali, Panchkula, Ambala, Bathinda, Patiala, Karnal, Panipat, Sonipat, Delhi, Gurugram - 03, Faridabad, Agra, Behror, Jaipur

Out of these, 06 hospitals were built organically. 10 hospitals have been acquired over last 16 yrs

Their new Hospital @ Panchkula ( largest ever Greenfield for the company ) and @ Agra ( largest ever acquisition ) - were both made in 2026

List of acquired hospitals -

Faridabad - 2011

Karnal - 2017

Ambala - 2020

Behror - 2021

Palam Vihar ( Gurugram ) - 2021

Sonipat - 2021

Jaipur - 2022

Mohali - 2023

Bathinda - 2025

Agra - 2026

Company’s upcoming hospitals -

Kanpur - acquired. Integration by Dec 26 ( have acquired a 55 pc stake )

Gorakhpur - acquired. Integration by Apr 27 ( have secured an operations and management agreement - not a typical acquisition )

Narela ( Delhi ) - acquired. Integration by Sep 26

Rohtak - Greenfield expansion. Should go live by Apr 2028

Brownfield expansion @ Ambala & Mohali

Cash on books @ 450 cr

Bed capacity to go upto 5500 by Mar 28 from 3600 currently

Company’s KRAs - North Clusters and Adjacent areas. Already the second largest chain in North India. Have a strong track record of acquisitions and turnarounds

Notes from Q4 concall -

Bathinda hospital was also acquired in FY 26

Narela hospital was also acquired LY via the IBC process

Q4 occupancy was @ 62 vs 59 YoY

High end treatments in - Cardiology, GI, Onco, Neuro, Ortho - account for 59 pc of company’s revenues

Performed 150 kidney transplants, 1200 Cardio procedures, 2600 - robo assisted knee and hip replacements in last FY

Raised 770 cr via IPO in FY 26 and repaid debt worth 380 cr. Gross Debt now stands @ 30 cr vs 450 cr @ the end of FY 25

Debtor days on 31 Mar 26 @ 129 days vs 165 days on 31 Mar 25 - due better payor mix and better management of Govt dues

Paid Rs 245 cr, 45 cr and 50 cr respectively for their hospital acquisitions @ Agra, Bathinda and Narela

Agra, Bathinda and Narela hospitals operated under Park MediWorld for 01, 08 and 03 months respectively in FY 26. Combined - they represent a bed capacity of aprox 500 beds. As these ramp up - should rub off positively on FY 27’s numbers. Panchkula Hospital also went live in April 26 ( another 300 + beds ) - should be another growth driver

Q4 ARPOB @ 29.7 k vs 28.5 k YoY

Park operates in the affordable space among the multi speciality players. Hence they also keep their ARPOBs in the affordable segment

Capex / Bed for a Greenfield capex is around 35 lakhs / bed. Greenfield capacities generally take about 6-8 months to breakeven on EBITDA basis

Their Bathinda hospital ( acquired hospital ) has already turned PAT positive

CGHS rates have recently been hiked by 13-15 pc

83 pc of company’s revenues come from Govt Schemes + PSU empanelment - this needs close monitoring and is a key risk - wrt long WC cycles + possibility of bad debts. Good thing here is that their max exposure is to Delhi + Haryana + Central Govts - they are fiscally healthy vs some other state Govts

After they complete their Mohali expansion of 150 beds, Park Medi shall become the biggest healthcare provider in the CHD tri-city ( taking their combined bed capacity @ Mohali + Panchkula to 850 beds ). Shall be catering to patients from HP, JK, Haryana, Punjab

Expecting Agra hospital to add 90 cr to their topline in FY 27 and should also be EBITDA positive for FY 27

Aim to gradually bring down their Govt + PSU business to 75 pc - over next 2 yrs and then to 70 pc within next 3 yrs

According to the management - UP is a great new mkt to enter and expand. Its a fast growing, large TAM, politically important state

The capex requirements for the company to bump their capacity to 5500 beds should be around 500 cr. Considering their cash position and internal accrual generation - this should not be a problem

Company works on a relatively lower cost model, has lower capex intensity / bed ( they also accommodate more beds / unit space ), operates @ lower ARPOB - these r deliberate business choices made by them - in line with their affordable positioning + bulk of business coming from Govt Scheme funded patients. They also focus actively manage their vendors and suppliers - pay on time and extract max possible discounts

Company’s disallowance rates remain at around 9 pc - wrt govt schemes - a key matrix to be tracked to arrive at the real health of the business. Plus transparency in its reporting and being conservative in its accounting treatment are absolutely non-negotiable

In this ’ affordable space + working with Govt ’ niche, Park Medi World is the only big player. There isn’t much of competition here

92 pc of Company’s Debtors lie with the central Govt

Disc: initiated a small tracking position, not SEBI registered, posted only for educational purposes, biased

3 Likes

Crompton Greaves Consumer Electricals ( showing promising signs of a turnaround ) -

Q4 and FY 26 results and concall highlights -

Q4 outcomes -

Revenues - 2283 vs 2061 cr

EBIT - 226 vs 228 cr ( EBIT margins @ 9.9 vs 11.1 pc - however, the margins have shown a descent uptick vs first 3Qs of FY 26 )

PBT ( before exceptional items ) - 232 vs 231 cr

EBIT margins showed improvement despite steep commodity price inflation - on the back of improved demand situation and price hikes taken by the company

Launched residential wires - Under the brand - ’ Crompton Armour ’ - in TN & Karnataka

ECD revenues @ 1755 vs 1603 cr

ECD EBIT @ 15.5 pc ( good recovery after a weak H1 )

ECD margins supported by strong demand for fans in Q4. Fans, small kitchen appliances also grew in double digits

Lighting revenues @ 316 vs 276 cr ( driven by double digit volume growth - both in residential and commercial segments )

Lighting EBIT @ 12.2 pc

Butterfly revenues @ 218 vs 187 cr

Butterfly EBIT @ 6 vs 5.8 pc

Butterfly’s growth led by electric cookers and induction cooktops. Relaunched breakfast series in Mar 26 ( like electric kettles, sandwich makers etc )

FY 26 outcomes -

Revenues - 8096 vs 7864 cr

EBIT - 656 vs 748 cr ( EBIT margins @ 8.1 vs 9.5 pc - Q1 and Q2 in current FY were subdued due weak summers in FY 26 )

PBT ( before exceptional items ) - 677 vs 756 cr

ECD revenues @ 6096 vs 6010 cr

ECD EBIT @ 13.3 pc

Lighting revenues @ 1085 vs 1020 cr

Lighting EBIT @ 142 vs 120 cr

Butterfly revenues @ 943 vs 865 cr

Butterfly EBIT @ 6 vs 4.9 pc

Notes from previous concalls -

Company has decided to enter Residential Wires and Cables segment wef Q4 FY 26 - it’s an adjacent category and company believes they have a right to win here given their strong brand pull

To begin with- company is going to outsource these products ( Wires and Cables ). Have worked on their go to mkt strategy in this segment over last 6-9 months

With solar rooftops + solar pumps + residential wires, company’s total addressable mkt doubles to 1.6 lakh cr vs 80k cr previously. This was critical to achieve from company’s long term growth potential’s PoV

Company’s 350 cr Greenfield capex to manufacture fans is progressing well. Should go commercial in FY 28

Entering wires and cables is a well thought out and a long term plan. They r very serious about the same. They r not entering this segment not for the sake of entering. Going forward - company is looking at exports of fans as a key focus area. Have hired a dedicated team for the same

As their scale in solar roof tops + solar pumps keeps improving - their Gross Margins in these segments are seeing an improving trend. This augurs really well for them as this would allow them to offer the best products at competitive prices to the B2C and B2G mkts

An avg Solar rooftop installation costs about 2-2.5 lakh for a 3 KW unit. Company aspires to scale up their Solar Pumps + Solar Rooftops business to 2000 cr + kind of annual run rate in next 24 months. Company believes, this is a sun rise business area for them

Notes from Q4 concall -

FY 26 was challenging - both from erratic weather and geopolitical PoV

BLDC fans grew 30 pc in Q4 vs Q4 LY

Launched Air Fryers, high end Juicers in Q4

Company’s standalone + butterfly’s Kitchen appliances business is showing very encouraging growth trends

Company is now No 2 player in water heaters in India

Company’s Consol EBITDA margins in Q4 stood @ 12 pc vs 9 pc in H1 - a sharp recovery

Have taken 2 price hikes - since the war started. Have taken these hikes ahead of the competition. They are hoping that competition also hikes and not get into price war. Management is very mindful of unit economics

Solar Pumps reported revenues of 200 cr in FY 25. In FY 26 - growth in solar pumps has been in very high double digits ( deliberately did not mention the exact quantum )

Have an order book of > 40k installations wrt their solar roof top ( each costing > Rs 2 lakh ) installations business. That’s an 800 cr order book. Have installed 5k out of these in Q4

Company’s B2B mix in their lighting business has shifted ( and is sifting continuously ) away from Govt contracts to private contractors. This is helping them improve margins here. Another factor helping the margins in greater sales of Panels / Downlights vs Battens / Bulbs in B2C segment. Also working on improving their supply chains in lighting

Margins in lighting have improved in FY 26 - despite materially higher investments in Advertisement and brand building

Have launched a new brand - ‘Crompton Rhion’ to sell appliances in the super premium segment

Management says - RoCE in their new businesses like ( Solar pumps, Solar rooftops, wires ) should be strong

Later in the concall, management did indicate that their solar pumps business has doubled to 400 cr vs 200 cr in FY 25

Large domestic appliances business - didn’t do well in FY 26, primarily due weak summers. Air coolers was the worst hit category

Have taken a hit of 703 cr ( non cash hit ) wrt write down of goodwill wrt Butterfly’s acquisition- made 2-3 yrs ago. Should lead to better PAT wef next FY as amortisation costs would fall

TN and Karnataka are 2 mkts where Crompton’s brand equity is very strong. Hence - have launched wires in these 2 mkts, to begin with

Shall be focusing on MBOs to push SDAs under Crompton and Butterfly brands. For LDAs and RHION branded products - shall focus more on Crompton EBOs. Have already opened 70 Crompton EBOs across the country

Crompton + Butterfly combined are already the second largest kitchen appliance brand in the country

Butterfly is very strong in Gas Stoves + Mixer Grinders in South India

Disc: hold an investment position, biased, not SEBI registered, posted only for educational purposes

1 Like

Akum Drugs -

Q4 and FY 26 results and concall highlights -

Q4 outcomes -

Revenues - 1158 vs 1056 cr, up 9 pc

EBITDA - 152 vs 94 cr, up 61 pc ( margins @ 13.1 vs 9 pc - significant margin expansion )

Finance costs @ 24 vs 5 cr

PAT @ 81 vs 150 cr ( LY - Q4 had a tax refund of 74 cr vs tax outgo of 40 cr in Q4 this FY )

Adjusted PAT @ 83 vs 35 cr, up 134 pc

Q4 Segmental revenues / EBITDA margins -

CMO - 952 vs 840 cr, up 13 pc. Margins @ 14.4 vs 10.6 pc

Domestic branded - 102 vs 104 cr, down 2 pc. Margins @ 21 vs 21 pc

International branded - 36 vs 40 cr, down 10 pc. Margins @ 28 vs 22 pc

Trade generics - 27 vs 22 cr, up 23 pc. Margins @ 14 vs (-) 10 pc

APIs - 41 vs 50 cr, down 19 pc. Margins @ (-) 29 vs (-) 12 pc

FY 26 outcomes -

Revenues - 4359 vs 4118 cr, up 6 pc

EBITDA - 522 vs 461 cr, up 13 pc ( margins @ 12 vs 11.2 pc )

Finance costs @ 94 vs 35 cr

PAT - 256 vs 344 cr ( due tax outgo of 126 vs 1 cr in current vs last FY )

Adjusted PAT @ 276 vs 217 cr, up 27 pc

FY 26 Segmental revenues / EBITDA -

CMO - 3485 cr, up 9 pc. Margins @ 13.4 vs 14.1 pc

Domestic branded - 446 cr, up 3 pc. Margins @ 20 vs 18 pc

International branded - 143 cr, flat YoY. Margins @ 25 vs 19 pc

Trade generics - 100 cr, down 13 pc. Margins @ (-) 10 vs (-) 28 pc

APIs - 184 cr, down 16 pc. Margins @ (-) 21 vs (-) 22 pc

Supplies to Zambia of aprox 235 cr / yr expected to be clocked for FY 27 and FY 28. Thereafter, supplies shall begin from their manufacturing facility @ Zambia

Domestic CMP growth for FY 27 to be led by new Onco and Steroid manufacturing lines

Overall capacity utilisation stands @ 44 pc - have a lot of scope for operational efficiencies

Notes from previous concalls -

Company’s top therapeutic areas wrt their domestic branded formulations include - paediatrics, gynaecology, cardiology

Company’s top destinations for their exports business include - Uganda, Nigeria, Philippines, Myanmar, Cambodia. Aim to ramp their exports business upto 900 cr / yr in next 5 yrs

Capex required in order to serve the European contract shall be around 200 cr ( to be incurred @ their Baddi plant ). The European contract should be a 320 - 340 cr / yr kind of business for the company, lasting 6 yrs ( starting Mar 2027 ). EBITDA margins should be around 14-15 pc wrt this contract

The API business that the company operates was acquired via IBC proceedings ( where in they acquired Parabolic drugs ). Company got credits against 870 cr of previous losses which they plan to utilise over next 3-4 yrs ( hence their tax rates shall continue to remain on the lower side )

Have received European approvals for 2 molecules - Rivaroxaban and Dapagliflozin. Company doesn’t have a field force in EU. Shall continue to supply / operate in EU mkts as a CMO supplier to other Pharma companies / Big Pharma distributors / participate in Tenders. Company expects their EU business to have better margins than their domestic CMO business. In next 3-4 yrs, company intends to own at least 10 sizeable dossiers in European mkts ( to supply to large distributors / participate in tenders ). This doesn’t include the large CMO contract from EU that the company has won and has got advance payment for

Company has filed for 2 Cephalosporin based Formulations in the EU mkts. Should get an approval in next 6 months. GMs in EU are better. This would help the company use its APIs captively and help improve the API business’s operating performance. Also the Cephalosporin API prices should start to recover in next 3-6 months

Charging notional interest of Rs 19 cr / Qtr to the P&L - against the advance they have got from the European major. Anyways, its a non cash entry

Open to inorganic opportunities ( actively evaluating the same ) to utilise the cash on books

Company has been commercialising their Injectables facilities in phases over last 2-3 Qtrs. Current capacity utilisation levels r on the lower side ( ie in teens ). Should start to contribute meaningfully to company’s CMO business by mid FY 27. At present, its loss making @ EBITDA level

Notes from Q4 concall -

Supplies to Zambia should begin in Q2 FY 27

Expecting to beat IPM in FY 27 wrt domestic branded business vs a paltry growth of 3 pc clocked in FY 26. However, they did improve their margins in FY 26. Similarly, expecting a growth revival in International branded business as well

Pricing pressures in Cephalosporins led to continued losses in their APIs business. Cost improvements + diversification into other APIs + Supplies to EU ( post European audit ) - should help them improve margins in this business

As their new facilities ramp up, capacity utilisations improve - should lead to better profitability going forward

Cash on books @ 1650 cr - a bulk of this is because of the advances received against the European contract ( ie 950 cr )

Regulated mkts play requires strict compliance @ their manufacturing sites. Since Akums already caters to Indian MNCs ( that too for a long time now ), Akums is capable of supplying and winning the regulated market spaces. The European contract won LY is a testament to their capabilities and compliance culture. Company already has one EUGMP approved facility each for Injectables, Oral Liquids ( it’s also approved by the Brazilian regulator ). Aim to get some more facilities approved by EU regulator in near future

As company’s supplies to regulated mkts improve ( over medium term ) it should be margin accretive @ GM and EBITDA levels

Have seen double digit volume growth in last 2 Qtrs in their CMO business. Should report double digit volume growth in CMO business in Q1 and Q2 as well. API prices have gone up in last 3-4 months, still lower than Mar 25 levels

Not looking to grow their trade generics business. Do aim to maintain the EBITDA positive state. Expecting to turn around their API business in FY 27

Q4 FY 25 EBITDA margins were exceptionally low

New Injectables facility’s currently operating with utilisation levels in early teens. Should ramp up significantly in FY 27

Expecting API losses to reduce significantly in FY 27

Brand building + Marketing led to improvement in margins in their international business in FY 26

Did not take any price hike in domestic branded business. As they hike prices in current yr + clock some volume growth, domestic branded business should also end up growing in double digits

De-Focusing from their trade generics business due elongated payment cycles

Capex for FY 26 stood @ 222 cr. Capex tgt for FY 27 @ 300 cr

Should be able to grow exports in double digits with stable margins in current FY

The double digit guidance in CMO business is without taking into account the Zambian contract

The manufacturing facility that they r building in Zambia - they shall have a 51 pc mkt share. Will be spending aprox 210 cr towards the same. Rest shall be contributed by the Zambian Govt

Disc: hold a small position, looking to add more on dips, not SEBI registered, posted only for educational purposes

1 Like

Dodla Dairy -

Q4 and FY 26 results and concall highlights -

Q4 outcomes -

Revenues - 1074 vs 909 cr

GMs @ 23 vs 27.2 pc

EBITDA - 53.8vs 83.5 cr, down 35 pc ( margins @ 5 vs 9.2 pc )

PAT - 70 vs 68 cr ( due one time tax credit of 29 cr )

Milk procurement @ 18.5 vs 16.3 LLPD, up 13 pc

Milk sales @ 14 vs 11.7 LLPD, up 19 pc

Curd sales @ 442 vs 383 MTPD

VAP sales @ 297 vs 284 cr ( @ 27 vs 31 pc of total sales )

Bulk sales in Q4 @ NIL vs 38 cr in Q4 LY

Higher milk procurement and sales in Q4 due to volume growth + integration of OSAM dairy

Curd sales grew by 15 pc

OSAM EBITDA margins are lower than company level margins

Milk sales in Africa grew by 63 pc. Africa business contributed 18 cr to consol EBITDA

Orgafeed sales grew by 23 pc, clocked EBITDA margins of 9.5 pc

FY 26 outcomes -

Revenues - 4125 vs 3720 cr

GMs @ 25.6 vs 27.4 pc

EBITDA - 308 vs 380 cr ( margins @ 7.5 vs 10.2 pc )

PAT - 267 vs 260 cr

Milk procurement @ 18.8 LLPD, up 10 pc

Milk sales @ 13.2 LLPD, up 13 pc

Curd sales @ 400 MTPD, up 8 pc

VAP sales @ 1199 cr

Planned Maharashtra Capex @ 590 cr. Have already spent 350 cr towards the same ( till now ). Shall increase company’s milk processing capacity by 15 LLPD. Shall also help them increase the VAP share in their total business mix. Shall spend the residual amount in FY 27. Out of this 10 LLPD shall go live by end of FY 27. Have already entered South Maharashtra to build brand awareness

Acquired OSAM dairy in Bihar for 247 cr in Jul 25. Added 2.2 LLPD to company’s capacity

Plan to invest 60 cr in African operations to expand capacity by 2 LLPD + increase in VAP product manufacturing. This should go live by end of FY 29

Company’s consol capacities -

Installed capacity @ 28 LLPD ( standalone capacity @ 21 LLPD )

18 milk processing plants ( 2 plants are in Africa, 2 plants added by OSAM acquisition )

1106 Dodla parlours

273 chilling plants

Cattlefeed capacity @ 480 MTPD

Orgafeed contributed to 164 cr in sales for FY 26

Have grown their VAP sales @ 20 pc CAGR in last 5 yrs. VAP contribution has grown from 25 to 29 pc over this period

Notes from Q4 concall -

Company’s diversification via Orgafeed, African and OSAM business is helping them tide over these difficult times

Milk procurement remained tight. Increased procurement prices - were not fully passed onto the consumers. Hence the dip in gross and EBITDA margins

Confident of improving VAP contribution to 32-34 pc over next 1-2 yrs

Africa business reported highest ever absolute EBITDA in Q4. In next 3-4 yrs, company aims to derive 15-18 pc of their topline from Africa - led by the expansion plans listed above

Orgafeed also reported a slight dip in margins in Q4 due higher RM costs

Avg procurement cost of milk in Q4 was @ Rs 41 vs Rs 37.4, up 9 pc YoY. Avg selling price was Rs 58.4 vs Rs 56.2, up 4 pc. This explains the compression in GMs and EBITDA in Q4

EBITDA contribution from Orgafeed + Africa business to company’s consol EBITDA in Q4 was 4 cr + 18 cr = 22 cr

Excluding bulk sales of butter + SMP ( low margin sales ), VAP products reported 21 pc YoY sales - an encouraging sign

Company expects some softening in input costs - should help margins, if that happens

Cash on books ( including liquid investments ) on 31 Mar @ 650 cr

Have declared a final dividend of Rs 5 / share

Guiding for an EBITDA margins of aprox 8 pc for FY 27 - guidance is on the conservative side keeping in view the current domestic and international uncertainities

Seeing good volume off takes in their line of products in Q1. Procurement prices continue to remain on the higher side. Hoping for stress in procurement to alleviate in month or so

Not planing to hike prices any time soon. Will work on better procurement and operational efficiencies for the time being

Expecting margins to revert to mean completely by FY 28 ( FY 27 should witness 100 bps kind of improvement vs FY 26 )

Anticipating the procurement prices to reduce by Rs 1 / lit by end of May / next month

VAP realisations in Q4 were @ Rs 60.3 / lit

OSAM’s revenues and EBITDA for Q4 stood @ 82 cr, 2.7 cr respectively. Their GMs were @ 21 pc. Management is confident of ramping them upto 25 pc in a short period of time

Logistics expenses in Q4 @ 7.3 pc, Packaging expenses @ 3.5 pc ( packaging expenses r included while calculating GMs ). Both these may surge if the Iran war continues

Quite confident that milk procurement prices should fall. Currently elevated levels r not sustainable - in their opinion

Seeing significant growth in VAP portfolio ( @ around 16-17 pc ) in Apr - May 26. Volume growth in milk in Apr-May has been around 5-6 pc

African business should grow by 20 pc in FY 27 - management sounded confident about the same. African business clocked sales of 500 cr and 11.3 pc EBITDA margins for FY 26

Disc : hold a small position, biased, not SEBI registered, posted only for educational purposes

1 Like